p53 与 MDM2：是拮抗剂还是共犯？
p53 and MDM2: antagonists or partners in crime?
作者信息
Eischen Christine M, Lozano Guillermina
机构信息
Department of Pathology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.
出版信息
Cancer Cell. 2009 Mar 3;15(3):161-2. doi: 10.1016/j.ccr.2009.02.004.
PMID:19249672
Abstract
Therapeutics that disrupt the p53-MDM2 interaction show promise for cancer treatment but surprisingly have different biological outcomes. A study by Enge et al. in this issue of Cancer Cell shows that the ability of MDM2 to target hnRNP K for degradation contributes to the decision to induce apoptosis rather than cell-cycle arrest.
摘要
破坏p53-MDM2相互作用的疗法在癌症治疗方面显示出前景，但令人惊讶的是会产生不同的生物学结果。恩格等人在本期《癌细胞》上发表的一项研究表明，MDM2将异质性核糖核蛋白K（hnRNP K）靶向降解的能力有助于决定诱导细胞凋亡而非细胞周期停滞。
Zotero 插件